Konruns(SH:603590)2023-04-25 16:00Financial Performance - In 2022, the company's operating revenue reached ¥866.73 million, an increase of 7.03% compared to ¥809.78 million in 2021[25]. - The net profit attributable to shareholders was ¥101.49 million, a decrease of 31.42% from ¥147.99 million in 2021[25]. - The net cash flow from operating activities increased by 68.79% to ¥119.69 million, compared to ¥70.91 million in 2021[25]. - Basic earnings per share decreased by 30.85% to ¥0.65, down from ¥0.94 in 2021[26]. - The weighted average return on equity fell to 3.49%, a decrease of 1.53 percentage points from 5.02% in 2021[26]. - The company's total assets at the end of 2022 were ¥3.42 billion, reflecting a 1.59% increase from ¥3.37 billion at the end of 2021[25]. - The company reported a decrease in net profit after deducting non-recurring gains and losses, which was ¥89.07 million, down 22.00% from ¥114.19 million in 2021[25]. - The company’s R&D expenses were 86.78 million RMB, down 15.15% from the previous year[90]. - The company’s sales expenses increased by 8.14% to 423.15 million RMB in 2022[90]. - The total sales expenses for the reporting period amounted to RMB 42,315.33 million, representing 48.82% of the operating income[140]. Dividend Distribution - The company plans to distribute a cash dividend of RMB 2.00 per 10 shares to all shareholders based on the total number of shares eligible for distribution as of the dividend record date[6]. - The company approved a cash dividend of RMB 3.00 per 10 shares, totaling RMB 46,947,413.10, which represents 31.72% of the net profit attributable to ordinary shareholders in the consolidated financial statements[190]. - For the 2022 profit distribution plan, the company plans to distribute RMB 2.00 per 10 shares, amounting to RMB 31,298,275.40, which is 30.84% of the net profit attributable to ordinary shareholders[191]. Corporate Governance - The company has not faced any penalties from securities regulatory agencies in the past three years[175]. - The company has not reported any significant differences in governance compared to regulatory requirements[160]. - The company has engaged Beijing DeHeng Law Offices to ensure the legality of the shareholders' meeting procedures[163]. - The company continuously improves its corporate governance structure and enhances information disclosure in compliance with relevant laws and regulations[160]. - The company held a shareholders' meeting on March 16, 2022, where several resolutions were passed, including extending the validity period for non-public issuance of A shares[160]. - The company has not identified any major issues regarding the independence of its controlling shareholders or actual controllers[160]. - The company has expanded its board with independent directors, enhancing governance and oversight[169]. - The company has undergone changes in its board, with several directors resigning for personal reasons and new appointments made, including the election of JIN LI as a director[174]. Research and Development - The company is focused on innovative drug research and development, aiming to become a high-quality Chinese pharmaceutical brand with a commitment to quality-driven growth[66]. - The company has established a four-tier talent system to enhance its innovative drug development capabilities[41]. - The company has received three domestic and international invention patents in 2022, bringing its total to 56 authorized patents[45]. - The company is advancing its innovative drug pipeline, including KC1036 and Jin Cao Pian, with the latter currently in Phase III clinical trials[38]. - The company is actively developing the KC1036 project, a multi-target receptor tyrosine kinase inhibitor with potential anti-tumor effects[117]. - The company has multiple ongoing R&D projects, including AH1001 for canine surgical wound treatment and KC1036 for advanced thymic tumors[128]. - The company’s R&D investment as a percentage of operating income was 14.72%, while the capitalized R&D expenditure accounted for 31.98% of total R&D spending[135]. - The company has increased its investment in construction projects, with in-progress projects rising by 43.00% to 181,983,116.14 RMB[107]. Market Position and Strategy - The company anticipates that 2023 will bring significant opportunities for innovation in the pharmaceutical sector, driven by favorable policies for innovative drug products[35]. - The company aims to achieve a sales target of at least 100 million yuan for "Suling" in 2023 by managing core hospitals and activating low-activity hospitals[37]. - The company has been recognized as a "specialized, refined, distinctive, and innovative small giant" and is focusing on developing innovative drugs as its main growth strategy[36]. - The company is committed to high-quality development in the pharmaceutical industry, driven by the ongoing healthcare reform and the "14th Five-Year Plan" for the medical sector[62]. - The company aims to achieve continuous revenue growth by focusing on the sales of innovative drugs, particularly "Suling," which has been included in the National Basic Medical Insurance Directory[150]. - The company plans to leverage the opportunity of "Suling" medical insurance renewal and lifting restrictions to expand market share in 2023[87]. Risk Management - The company has outlined various risk factors and countermeasures that may affect its future development strategies and operational goals[10]. - The company acknowledges the impact of evolving industry policies and will proactively adapt to changes to mitigate risks and seize opportunities[157]. - The company is committed to addressing new drug development risks by intensifying resource allocation to key projects and enhancing collaboration with renowned research institutions[156]. Employee Management - The total number of employees in the parent company and major subsidiaries is 449, with 190 in sales, 100 in technology, and 82 in production[186]. - The company has established a three-tier training system to enhance employees' professional and managerial skills, covering various aspects including corporate culture and regulations[188]. - The company has implemented a salary policy that links compensation to company and individual performance, aiming to motivate employees[187]. - The company has established a performance evaluation mechanism for senior management, linking compensation to company performance and operational goals[198]. Legal and Compliance - The company has not reported any significant changes in competition or business operations affecting its independence[160]. - The company has not faced any non-operating fund occupation by controlling shareholders or related parties[8]. - The company has not violated decision-making procedures in providing guarantees to external parties[8]. - The company has made amendments to its articles of association and various management systems during the meetings[163].